Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04025216 · ClinicalTrials.gov registry record · Phase 1
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04025216 is a Phase 1 study that was terminated before completion, run by Kite, A Gilead Company. The registered enrollment target is 16 participants.
The verdict
NCT04025216, a Phase 1 study, was terminated before completion, sponsored by Kite, A Gilead Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL CART-TnMUC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-10-10 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04025216
The ClinicalTrials.gov registry entry for NCT04025216 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04025216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04025216 about?
NCT04025216 is a clinical study titled "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers". Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor anti...
What is the current status of trial NCT04025216?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-10-10. Estimated completion is 2022-12-02.
What interventions are being tested in trial NCT04025216?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CART-TnMUC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04025216?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.